Table 1.

Ongoing clinical trials targeting the HER2 receptor.

Drug	Phase	Primary Outcome	Status	ID
Trastuzumab	II	ORR (12 months)	Recruiting	NCT04482309
Trastuzumab	I/II	RP2D, ORR (12 months)	Not yet recruiting	NCT04464967
Zenocutuzumab	I/II	AE, SAE, ORR (36 months), DOR (36 months), correlation of anti-tumour activity and biomarkers	Recruiting	NCT02912949
Afatinib	I/II	AE, PK, ORR (20 months)	Recruiting	NCT03785249

ORR, objective response rate; RP2D, recommended phase II dose; AE, adverse events; SAE, serious adverse events; DOR, duration of response; PK, pharmacokinetics.